182 related articles for article (PubMed ID: 22300987)
1. Carboxy-terminus of CXCR7 regulates receptor localization and function.
Ray P; Mihalko LA; Coggins NL; Moudgil P; Ehrlich A; Luker KE; Luker GD
Int J Biochem Cell Biol; 2012 Apr; 44(4):669-78. PubMed ID: 22300987
[TBL] [Abstract][Full Text] [Related]
2. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
[TBL] [Abstract][Full Text] [Related]
3. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
4. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
5. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
6. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
7. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
[TBL] [Abstract][Full Text] [Related]
8. CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.
Torossian F; Anginot A; Chabanon A; Clay D; Guerton B; Desterke C; Boutin L; Marullo S; Scott MG; Lataillade JJ; Le Bousse-Kerdilès MC
Blood; 2014 Jan; 123(2):191-202. PubMed ID: 24277075
[TBL] [Abstract][Full Text] [Related]
9. Receptor sequestration in response to β-arrestin-2 phosphorylation by ERK1/2 governs steady-state levels of GPCR cell-surface expression.
Paradis JS; Ly S; Blondel-Tepaz É; Galan JA; Beautrait A; Scott MG; Enslen H; Marullo S; Roux PP; Bouvier M
Proc Natl Acad Sci U S A; 2015 Sep; 112(37):E5160-8. PubMed ID: 26324936
[TBL] [Abstract][Full Text] [Related]
10. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues.
Hoffmann F; Müller W; Schütz D; Penfold ME; Wong YH; Schulz S; Stumm R
J Biol Chem; 2012 Aug; 287(34):28362-77. PubMed ID: 22736769
[TBL] [Abstract][Full Text] [Related]
11. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
12. Differential Involvement of ACKR3 C-Tail in β-Arrestin Recruitment, Trafficking and Internalization.
Zarca A; Perez C; van den Bor J; Bebelman JP; Heuninck J; de Jonker RJF; Durroux T; Vischer HF; Siderius M; Smit MJ
Cells; 2021 Mar; 10(3):. PubMed ID: 33799570
[No Abstract] [Full Text] [Related]
13. The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation.
Estall JL; Koehler JA; Yusta B; Drucker DJ
J Biol Chem; 2005 Jun; 280(23):22124-34. PubMed ID: 15817468
[TBL] [Abstract][Full Text] [Related]
14. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7.
Kohout TA; Nicholas SL; Perry SJ; Reinhart G; Junger S; Struthers RS
J Biol Chem; 2004 May; 279(22):23214-22. PubMed ID: 15054093
[TBL] [Abstract][Full Text] [Related]
15. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis.
Alampour-Rajabi S; El Bounkari O; Rot A; Müller-Newen G; Bachelerie F; Gawaz M; Weber C; Schober A; Bernhagen J
FASEB J; 2015 Nov; 29(11):4497-511. PubMed ID: 26139098
[TBL] [Abstract][Full Text] [Related]
16. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.
Décaillot FM; Kazmi MA; Lin Y; Ray-Saha S; Sakmar TP; Sachdev P
J Biol Chem; 2011 Sep; 286(37):32188-97. PubMed ID: 21730065
[TBL] [Abstract][Full Text] [Related]
17. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
Maussang D; Mujić-Delić A; Descamps FJ; Stortelers C; Vanlandschoot P; Stigter-van Walsum M; Vischer HF; van Roy M; Vosjan M; Gonzalez-Pajuelo M; van Dongen GA; Merchiers P; van Rompaey P; Smit MJ
J Biol Chem; 2013 Oct; 288(41):29562-72. PubMed ID: 23979133
[TBL] [Abstract][Full Text] [Related]
18. Proline-rich motifs in the parathyroid hormone (PTH)/PTH-related protein receptor C terminus mediate scaffolding of c-Src with beta-arrestin2 for ERK1/2 activation.
Rey A; Manen D; Rizzoli R; Caverzasio J; Ferrari SL
J Biol Chem; 2006 Dec; 281(50):38181-8. PubMed ID: 17038311
[TBL] [Abstract][Full Text] [Related]
19. CXCR7 impact on CXCL12 biology and disease.
Sánchez-Martín L; Sánchez-Mateos P; Cabañas C
Trends Mol Med; 2013 Jan; 19(1):12-22. PubMed ID: 23153575
[TBL] [Abstract][Full Text] [Related]
20. AMD3100 is a CXCR7 ligand with allosteric agonist properties.
Kalatskaya I; Berchiche YA; Gravel S; Limberg BJ; Rosenbaum JS; Heveker N
Mol Pharmacol; 2009 May; 75(5):1240-7. PubMed ID: 19255243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
